Understand the source comparison
Mechanism of Action: How Peptides vs SARMs Achieve Anabolic Effects
Peptides function as endogenous signaling molecules—amino acid sequences that bind cell surface receptors to trigger downstream hormone cascades. Growth hormone-releasing peptides (GHRP-2, GHRP-6, Ipamorelin) bind ghrelin receptors in the anterior pituitary, s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptides function as endogenous signaling molecules—amino acid sequences that bind cell surface receptors to trigger downstream hormone cascades. Growth hormone-releasing peptides (GHRP-2, GHRP-6, Ipamorelin) bind ghrelin receptors in the anterior pituitary, stimulating somatotroph cells to secrete endogenous growth hormone in pulsatile fashion—mimicking natural circadian release patterns rather than replacing them. CJC-1295 (a GHRH analogue) extends this pulse duration by resisting enzymatic degradation, but the growth hormone itself originates from your pituitary stores.
- MK-677 (ibutamoren) is technically a growth hormone secretagogue, not a peptide—it's a small molecule ghrelin receptor agonist with a 4–6 hour half-life that produces sustained GH elevation over 24 hours. Despite oral bioavailability, it still works through endogenous axis stimulation rather than receptor occupation.
- SARMs operate through a completely different pathway. These synthetic ligands bind androgen receptors (AR) in skeletal muscle and bone tissue with high affinity but lower affinity for prostate and sebaceous glands—the "selectivity" in their name. Ostarine (MK-2866), ligandrol (LGD-4033), and testolone (RAD-140) occupy the same receptor sites as testosterone and DHT but with tissue-selective activation profiles. When a SARM binds an androgen receptor, it triggers conformational changes that promote AR translocation to the cell nucleus, DNA binding, and transcription of anabolic genes (myosin heavy chain, IGF-1, follistatin). Unlike testosterone, most SARMs don't convert to estrogen via aromatase or to DHT via 5-alpha reductase—reducing but not eliminating androgenic side effects.
- The critical distinction: peptides require a functional endogenous axis. If your pituitary is suppressed or your GH receptor signaling is impaired, peptides will underperform. SARMs bypass this entirely—they work even when natural testosterone production is suppressed, which is why they suppress the hypothalamic-pituitary-gonadal (HPG) axis as a secondary effect. Peptide use typically does not suppress endogenous hormone production because negative feedback mechanisms remain intact. SARM use almost always suppresses LH and FSH secretion because exogenous androgen receptor activation signals the hypothalamus that sufficient androgens are present, downregulating gonadotropin release.
- Real Peptides synthesizes compounds like Tesamorelin (a GHRH analogue FDA-approved for lipodystrophy) and Sermorelin (1–29 fragment of GHRH) specifically because they amplify natural processes rather than override them—critical for long-term research applications where axis preservation matters.